Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003250 · ClinicalTrials.gov registry record · Phase 1
Fenretinide in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00003250: Completed Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00003250 is a Phase 1 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003250, a Phase 1 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of fenretinide in treating patients who have solid tumors.
Primary Outcome
When drug is administered orally three times daily for 21 doses, repeated every 21 days.
Interventions
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 1998-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
What the finished NCT00003250 record still lists
NCT00003250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which fenretinide is the first listed.
NCT00003250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003250 about?
NCT00003250 is a clinical study titled "Fenretinide in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of fenretinide in treating patients who have solid tumors.
What is the current status of trial NCT00003250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 1998-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00003250?
The interventions under investigation include: fenretinide (DRUG).
Who is sponsoring clinical trial NCT00003250?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003250's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia